Physician profile
Vikram Singh
NPI 1306904727
$3,563.67
in general payments reported to CMS, 2019-2025
21 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $199 · 2021: $236 · 2022: $856 · 2023: $518 · 2024: $711 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $726.17 | 2021-2025 | Intellis Adaptivestim, Mazor X System |
| Linvatec Corporation | $634.36 | 2022-2023 | Biobrace 23mm, Linvatec Shoulder Arthroscopy, Linvatec Extremities |
| Boston Scientific Corporation | $522.80 | 2020-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Abbott Laboratories | $294.97 | 2019-2025 | Eterna, Proclaim |
| Vertiflex, INC. | $247.64 | 2019 | |
| Indivior INC. | $231.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.61 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Camzyos |
| Painteq LLC | $94.98 | 2024 | Painteq |
| Pfizer INC. | $80.42 | 2020 | |
| Spr Therapeutics, INC | $73.31 | 2024 | Sprint Pns System |
| Daiichi Sankyo INC. | $66.62 | 2019 | |
| Redhill Biopharma INC. | $54.72 | 2020-2021 | |
| Ziehm-Orthoscan, INC. | $48.06 | 2019 | |
| Collegium Pharmaceutical, INC. | $32.84 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $30.74 | 2025 | |
| Alexion Pharmaceuticals, INC. | $25.61 | 2021 | |
| Fidia Pharma USA INC. | $25.20 | 2024 | Triluron, Hymovis, Hyalgan |
| Virtus Pharmaceuticals LLC | $18.17 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.38 | 2019 | |
| Ibsa Pharma INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.